Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
WEBINAR | Cracking the code: learnings from oligonucleotide method development WATCH NOW

Spotlight survey on antibody-drug conjugates

14 Apr 2015
General interest

As part of our Spotlight on antibody-drug conjugates (ADCs), Bioanalysis Zone carried out a survey to investigate the techniques used to study ADCs, the issues surrounding their analysis, as well as what the future may hold.

The results can be seen via our infographic. We will also be analyzing the results of the survey during our Spotlight panel discussion, which you can register for here.

 

Top content

  • AAPS PharmSci 360 2025: conference highlights
  • The NAD dash: inside the molecule making longevity a measurable science
  • From the floor at AAPS PharmSci 360 2025

Related tags

ADCs
Previous article Next article

Related articles

20 JUN 2014 GENERAL INTEREST
Intertek highlights bioanalytical and analytical solutions for antibody drug conjugates at National Biotechnology Conference (AAPS NBC)
4 JUN 2013 GENERAL INTEREST
Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers’ perspective
11 OCT 2017 NEWS
PPD are awarded best CRO for advancing cancer research at World ADC Awards
payload
10 FEB 2025 ANTIBODIES | ADCS
Challenges and advances in payload analysis for antibody-drug conjugates: a CRO perspective
30 JAN 2014 GENERAL INTEREST
Hot topics in antibody-drug conjugate development
13 JUL 2016 JOURNAL ARTICLES
Antibody–drug conjugate bioanalysis using LB-LC–MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone